Specioside

Specioside at a Glance

Specioside is a catalpol-type iridoid glycoside — structurally, the 6-O-p-coumaroyl ester of catalpol, a bitter iridoid glucoside decorated with a p-coumaric-acid group. It is a Bignoniaceae signature compound, first isolated from northern catalpa (Catalpa speciosa), from which it takes its name, and later characterised in the bark of the Tabebuia/Handroanthus trees sold as pau d’arco (taheebo).

As an isolated molecule, specioside is very data-thin. The published record is essentially three small studies: an in-vitro report that it activates the Keap1–Nrf2 antioxidant pathway and protects liver cells from oxidative stress ^{3Reference 3Garzón-Castaño SC et al. · 2020Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DCView study →}; a rodent study showing a modest anti-inflammatory effect while most other tested activities were negligible ^{5Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}; and an in-vitro finding that it can push leukaemia cells toward apoptosis, but only in combination with a separate drug ^{4Reference 4Guerrero-Pepinosa NY et al. · 2024The n-butanol extract obtained from the inner bark of Tabebuia rosea (Bertol.) DC, specioside, and catalposide induce leukemia cell apoptosis in the presence of apicidinView study →}. An early attempt at antimicrobial activity was negative ^{2Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →}.

The honest framing matters most here. In pau d’arco, the human-relevant evidence is for the whole inner bark, and its medicinal reputation rests on the naphthoquinones lapachol and beta-lapachone — not on this minor iridoid. Nothing below should be read as pau d’arco pharmacology; it is the thin dossier of one isolated constituent.

Specioside as a Catalpol Ester

Specioside is best understood as a decorated catalpol. Catalpol is a small, widespread C9 iridoid glucoside (the parent iridoid of catalpa, foxglove, Rehmannia and many Lamiales); specioside is its 6-O-ester with (E)-p-coumaric acid — hence the systematic name 6-O-p-coumaroylcatalpol ^{1,2Reference 1El-Naggar SF · 1980Specioside: a new iridoid glycoside from Catalpa speciosaView study →Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →}. That single acyl group is the whole difference between the two molecules: an iridoid glucoside core plus a p-coumaroyl “hat.” (Catalpol does not yet have its own page here; it is being built in parallel.) The related catalposide — the 6-O-p-hydroxybenzoyl ester of catalpol — co-occurs with specioside in the same barks and is repeatedly studied alongside it ^{4Reference 4Guerrero-Pepinosa NY et al. · 2024The n-butanol extract obtained from the inner bark of Tabebuia rosea (Bertol.) DC, specioside, and catalposide induce leukemia cell apoptosis in the presence of apicidinView study →}.

Where it occurs. Specioside is a Bignoniaceae iridoid. It was named in 1980 from Catalpa speciosa ^{1Reference 1El-Naggar SF · 1980Specioside: a new iridoid glycoside from Catalpa speciosaView study →} and confirmed in 1982 from Tabebuia rosea ^{2Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →}; it is also reported from Tabebuia aurea stem bark ^{5Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →} and, outside the family, from Veronica peregrina. It sits within the broader class of iridoid glycosides that also includes aucubin and the Harpagophytum iridoid harpagide — all bitter, defensive plant glucosides.

Honest status in pau d’arco. In the Tabebuia/Handroanthus bark used medicinally, specioside is a minor constituent. The herb’s characteristic — and best-studied — chemistry is its naphthoquinones, principally lapachol and beta-lapachone, which carry essentially all of pau d’arco’s antimicrobial and anticancer research interest. Specioside is not the reason anyone drinks the tea.

What real isolate screening exists. Very little, and it is mixed. The isolate activates Nrf2 and protects hepatocytes from H₂O₂ in cell culture ^{3Reference 3Garzón-Castaño SC et al. · 2020Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DCView study →}; it showed a modest anti-inflammatory effect in a mouse peritonitis model, while its antibacterial, antibiofilm, cytotoxic, anti-Trichomonas and antitrypanosomal activities were reported as negligible ^{5Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}; and the earliest isolation study found it failed to show antimicrobial activity despite the plant’s traditional antimalarial/anti-infective use ^{2Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →}. Isolate data are, plainly, minimal — enough to sketch a preclinical antioxidant/anti-inflammatory hint, not to claim a pharmacology.

What It's Used For

Specioside’s evidence is entirely preclinical and sparse — a handful of in-vitro and single-species rodent studies on the isolate, with no human data. Read the per-row basis; each rests on one or two reports.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here rests on one or two isolate studies with no human data, so scores stay low by design.

01Antioxidant / Nrf2 cytoprotectionShaky34%One in-vitro isolate study: Keap1–Nrf2, HMOX-1/NQO1, HepG2 H₂O₂ protection ^{3Reference 3Garzón-Castaño SC et al. · 2020Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DCView study →}

02Anti-inflammatoryShaky30%One rodent isolate study (carrageenan peritonitis); other activities negligible ^{5Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}

03Pro-apoptotic (conditional)Shaky20%One in-vitro isolate study, apoptosis only with apicidin ^{4Reference 4Guerrero-Pepinosa NY et al. · 2024The n-butanol extract obtained from the inner bark of Tabebuia rosea (Bertol.) DC, specioside, and catalposide induce leukemia cell apoptosis in the presence of apicidinView study →}

Mechanisms

The load-bearing point is how little there is: one in-vitro Nrf2 result, one rodent anti-inflammatory result, and one drug-combination apoptosis result. No mechanism has been reproduced across labs for the isolate.

Pharmacokinetics

There are no dedicated pharmacokinetic data for specioside — no measured oral bioavailability, half-life or metabolite profile for the isolate. What can be said is class-level: catalpol-type iridoid glucosides are polar, water-soluble molecules that are typically poorly absorbed orally, are prone to acid degradation in the stomach, and are cleaved by gut and tissue β-glucosidase to an unstable aglycone — the same limitation documented for related iridoids such as aucubin (oral bioavailability ~19% in rats). The added p-coumaroyl ester does not change that basic expectation. The practical consequence is that in-vitro potency (e.g. the Nrf2/HepG2 result) almost certainly overreads what an oral dose of the whole herb could deliver.

Clinical Trials

There are no clinical trials of specioside — not as an isolate and not as a named active. The only human-facing evidence for its plant sources is for whole pau d’arco (taheebo) inner bark, where specioside is a minor iridoid and any studied effect is attributed to the naphthoquinones, not to this compound.

Last checked: July 2026.

Isolate vs. Plant Studies

The split is stark and points the same way. Every specioside-specific result — Nrf2/HepG2 cytoprotection ^{3Reference 3Garzón-Castaño SC et al. · 2020Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DCView study →}, the carrageenan anti-inflammatory signal ^{5Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}, the apicidin-dependent apoptosis ^{4Reference 4Guerrero-Pepinosa NY et al. · 2024The n-butanol extract obtained from the inner bark of Tabebuia rosea (Bertol.) DC, specioside, and catalposide induce leukemia cell apoptosis in the presence of apicidinView study →}, the negative antimicrobial screens ^{2,5Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →} — is isolate work in cells or single rodent models, with no human data at all. On the plant side, the human-relevant evidence belongs to whole pau d’arco bark, whose activity is carried by the naphthoquinones lapachol and beta-lapachone; specioside is a minor iridoid in that matrix and is not the tested agent. So the isolate has a thin, honest preclinical file of its own, but it cannot borrow credibility from pau d’arco’s reputation — that reputation is about different molecules.

Prevalence in Nature

Specioside is a Bignoniaceae iridoid. It was first isolated from northern catalpa (Catalpa speciosa) ^{1Reference 1El-Naggar SF · 1980Specioside: a new iridoid glycoside from Catalpa speciosaView study →}, and is a documented constituent of the Tabebuia/Handroanthus barks used as pau d’arco — confirmed in Tabebuia rosea ^{2Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →} and reported from Tabebuia aurea stem bark ^{5Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}. Outside the family it occurs in Veronica peregrina (Plantaginaceae) among other iridoid-scavenging genera. Like other iridoid glucosides it is a bitter, defensive compound, stored inert and activated by β-glucosidase on tissue damage; its absolute concentration is rarely quantified as % dry weight, and in pau d’arco it is present at minor levels relative to the naphthoquinones — so no reliable cross-source concentration ranking exists, a gap tracked for a later pass rather than asserted here.

Major Natural Sources

Source (botanical)	Family	Plant part	Notes
Northern catalpa (Catalpa speciosa)	Bignoniaceae	Bark / tissues	Namesake source; where specioside was first isolated 1Reference 1El-Naggar SF · 1980Specioside: a new iridoid glycoside from Catalpa speciosaView study →
Pau d’arco (Tabebuia rosea)	Bignoniaceae	Bark	Structure confirmed here as 6-O-p-coumaroylcatalpol 2Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →
Pau d’arco (Tabebuia aurea)	Bignoniaceae	Stem bark	Source of the anti-inflammatory isolate study 5Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →
Veronica peregrina	Plantaginaceae	Aerial parts	Among antioxidative iridoids reported from the genus

In pau d’arco (also from Handroanthus impetiginosus and related species), specioside is a minor iridoid; the herb’s studied actives are the naphthoquinones lapachol and beta-lapachone.

Discovery & Synthesis

Specioside was first isolated and named in 1980 by Sha’ban F. El-Naggar and Raymond W. Doskotch, who characterised it as a new iridoid glycoside from Catalpa speciosa — the species that gives the molecule its name ^{1Reference 1El-Naggar SF · 1980Specioside: a new iridoid glycoside from Catalpa speciosaView study →}. Two years later, Compadre and colleagues (1982) isolated the same compound from the bark of Tabebuia rosea, confirming its structure as 6-O-(p-coumaroyl)-catalpol by spectroscopy; notably, although the plant’s traditional infusions were reputed antimalarial, the purified iridoid failed to show antimicrobial activity ^{2Reference 2Compadre CM et al. · 1982Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia roseaView study →}.

There is no well-documented total synthesis of specioside; as with most iridoid glucosides, research supply is by extraction from catalpa or Tabebuia bark (or purchase as a reference standard), since the molecule is a straightforward p-coumaroyl ester of the naturally abundant catalpol rather than a synthetic target.

Patents: not yet researched.

Toxicity & Safety

Specioside carries a low flag — it is a bitter iridoid glucoside of the same broad class as many dietary and medicinal plant iridoids, with no toxicity signal reported at the doses used in its (few) rodent and cell studies ^{3,5Reference 3Garzón-Castaño SC et al. · 2020Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DCView study →Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}. As with related iridoids, the rating stays “low” rather than “none” because no dedicated isolate toxicology exists: there is no LD50, genotoxicity or repeat-dose package for the pure compound, and no reproductive or developmental data. Any pregnancy or lactation caution around pau d’arco belongs to the source herb and its naphthoquinones (lapachol is a documented reproductive/haematological concern), and that decision lives on the herb page, not on this molecule page.

Safety at a Glance

✅ Low / no toxicity

• A low-toxicity plant iridoid. Same broad class as widely consumed iridoid glucosides; no acute toxicity signal in the small isolate studies to date ^{3,5Reference 3Garzón-Castaño SC et al. · 2020Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DCView study →Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}.
• Real-world exposure is tiny. In pau d’arco it is a minor constituent; whole-bark intake delivers little specioside relative to the herb’s naphthoquinones.
• The safety story of pau d’arco is not this molecule’s. The herb’s meaningful toxicity concerns track its naphthoquinone lapachol (vitamin-K antagonism, dose-dependent effects), not specioside.
• No isolate toxicology. No LD50, genotoxicity, repeat-dose or reproductive data for the pure compound; safety is inferred from class, not measured.

Dosage

There is no established or recommended human dose for isolated specioside — it has never been given to people as an isolate for therapy. The figures in the literature are in-vitro concentrations and rodent research doses (e.g. the Nrf2/HepG2 and carrageenan-peritonitis studies ^{3,5Reference 3Garzón-Castaño SC et al. · 2020Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DCView study →Reference 5Nocchi SR et al. · 2020Pharmacological properties of specioside from the stem bark of Tabebuia aureaView study →}), which are experimental tools, not recommendations, and do not translate to an oral human dose given the poor oral bioavailability expected of iridoid glucosides. Human exposure is indirect, through whole pau d’arco (taheebo) inner-bark preparations, in which specioside is a minor iridoid and the studied activity belongs to the herb’s naphthoquinones. These are doses studied in research and are not a personal recommendation.

References

1. El-Naggar SF, Doskotch RW (1980). Specioside: a new iridoid glycoside from Catalpa speciosa. Journal of Natural Products, 43(4):524–526. https://doi.org/10.1021/np50010a015
2. Compadre CM, Jáuregui JF, Nathan PJ, Enríquez RG (1982). Isolation of 6-O-(p-coumaroyl)-catalpol from Tabebuia rosea. Planta Medica, 46(1):42–44. https://pubmed.ncbi.nlm.nih.gov/17396938/
3. Garzón-Castaño SC, Jiménez-González FJ, Veloza LA, Sepúlveda-Arias JC (2020). Activation of the Keap1-Nrf2 pathway by specioside and the n-butanol extract from the inner bark of Tabebuia rosea (Bertol) DC. F1000Research, 9:1262. https://pubmed.ncbi.nlm.nih.gov/33214880/
4. Guerrero-Pepinosa NY, Veloza LA, Sepúlveda-Arias JC (2024). The n-butanol extract obtained from the inner bark of Tabebuia rosea (Bertol.) DC, specioside, and catalposide induce leukemia cell apoptosis in the presence of apicidin. Molecules, 29(17):3986. https://pubmed.ncbi.nlm.nih.gov/39274835/
5. Nocchi SR, Kato NN, de Almeida JM, et al. (2020). Pharmacological properties of specioside from the stem bark of Tabebuia aurea. Revista Brasileira de Farmacognosia, 30:118–122. https://doi.org/10.1007/s43450-020-00017-5
6. Garzón-Castaño SC, Lopera-Castrillón IA, Jiménez-González FJ, Siller-López F, Veloza LA, Sepúlveda-Arias JC (2018). Nrf2-mediated antioxidant activity of the inner bark extracts obtained from Tabebuia rosea (Bertol) DC and Tabebuia chrysantha (JACQ) G. Nicholson. F1000Research, 7:1937. https://pubmed.ncbi.nlm.nih.gov/30728952/

View all 6 references▾